Valeant Pharmaceuticals International (NYSE: VRX, effective November 14, 2003) is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products. (NOTE: Formerly known as ICN Pharmaceuticals)

One Enterprise
Aliso Viejo, California 92656
  949 461-6000
  info@valeant.com

Demand for medicines to treat psychiatric and neurological disorders is huge and growing. Worldwide spending for these therapies exceeded $46 billion in 2001. The Central Nervous System (CNS) medication market is the fastest growing of any major therapeutic area. Vela Pharmaceuticals Inc. (VelaPharm) "rediscovers" and develops CNS medicines. By starting with molecules that have already been tested in humans, VelaPharm minimizes the risks of traditional drug discovery and development. Partnering with VelaPharm is an attractive alternative for pharmaceutical companies with assets on the backburner. Taking full or partial ownership of such assets, the VelaPharm team puts it all into safe, efficient and fast development. The Company's ability to design and run optimal Phase II CNS programs is second to none. VelaPharm already has several promising assets in clinical development. VelaPharm is led by experienced CNS pharmaceutical and CRO executives. VelaPharm's President and CEO is Kevin L. Keim, Ph.D., the former president of Quintiles' CNS Therapeutics group. He has recruited top performers from such organizations as Quintiles, Wyeth-Ayerst, Roche, Merck & Co., McKinsey & Company, and the National Institute of Mental Health. Based in Lawrenceville, NJ, VelaPharm was incorporated in 1998. The company is backed by venture funding from JP Morgan Partners, New Enterprise Associates, Venrock, and others.

Lawrenceville, New Jersey
  609-895-8352
  info@velapharm.com

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a global biotechnology company. Vertex seeks to discover, develop, and commercialize major pharmaceutical products independently and with partners. Chemogenomics, Vertex's proprietary, systematic, genomics-based platform, is designed to accelerate the discovery of new drugs and to expand intellectual property coverage of drug candidate compounds and classes of related compounds. This approach, which targets gene families, has formed the basis for several commercial collaborations under which Vertex retains rights to downstream revenue. Vertex's first approved product is Agenerase® (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with GlaxoSmithKline. Vertex has more than 12 drug candidates in clinical and preclinical development to treat viral diseases, inflammation, cancer, autoimmune diseases, neurological disorders and genetic disorders.

Cambridge, Massachusetts

Vysis, Inc., a wholly-owned subsidiary of Abbott Laboratories, is a leading Genomic Disease Management company that develops, commercializes and markets DNA-based clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis, originally Imagenetics Incorporated, was incorporated in 1991 as a division of Amoco Technology Company (a wholly-owned subsidiary of Amoco Corporation), and made its initial public offering of stock in 1998. The company was listed on the NASDAQ® stock exchange between 1998 and 2001. In October, 2001, Abbott Laboratories acquired Vysis as a wholly-owned subsidiary. The transaction was completed on December 5, 2001.

Downers Grove, Illinois
  customerservice@vysis.com

Watson Pharmaceuticals, Inc. has evolved into a specialty pharmaceutical company, focused on developing, manufacturing and marketing brand and generic pharmaceutical products utilizing various drug delivery technologies. These technologies include solid dosage form, oral controlled release, transdermal, oral transmucosal and drug cell targeting delivery systems.

Corona, California

Wyeth (formerly American Home Products Corporation) is a research-based, global pharmaceutical company responsible for the discovery and development of some of today's most innovative medicines. Our products are sold in more than 140 countries, and our product portfolio includes innovative treatments across a wide range of therapeutic areas. Our worldwide resources include more than 52,000 employees, manufacturing facilities on five continents, and a discovery and development platform encompassing pharmaceuticals, vaccines and biotechnology.

Madison, New Jersey

Xenon Pharmaceuticals Inc. is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases.

3650 Gilmore Way
Burnaby, BC, Canada V5G 4W8
  604.484.3300
  info@xenon-pharma.com

XOMA (US) LLC XOMA develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets that include immunological and inflammatory disorders, cancer and infectious diseases. XOMA's programs include collaborations: with Genentech, Inc. on the Raptiva(TM) antibody for psoriasis (BLA submission), psoriatic arthritis (Phase II) and other indications; and with Millennium Pharmaceuticals, Inc. on two biotherapeutic agents, CAB-2 and MLN2201, for vascular inflammation indications (preclinical and phase I, respectively). Earlier-stage development programs focus on antibodies and other compounds developed by XOMA for the treatment of cancer, retinopathies and acne.

2910 Seventh Street
Berkeley, California 94710
  InvestorRelations@xoma.com

Incorporated in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen's novel molecules were developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (alpha-MSH). A naturally occurring molecule, alpha-MSH modulates inflammatory and immune responses. James Lipton, Ph.D., Zengen's chief scientific officer, chairman of the scientific advisory board and director, and his collaborators first demonstrated that alpha-MSH possesses anti-inflammatory properties and uncovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the alpha-MSH peptide. These discoveries led to the development of Zengen's proprietary peptide molecules, including CZEN 002, a synthetic octapeptide. There is abundant evidence of the anti-inflammatory and anti-infective activity of these novel molecules from both in vivo and in vitro research. Zengen is currently conducting phase I/II clinical trials with CZEN 002 in vaginitis.

Woodland Hills, California

ZIOPHARM, Inc. is a privately held company founded in January 2004 to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs. All products are focused on addressing unmet medical needs, with the potential for expedited approval and broad usage. ZIOPHARM's first product, ZIO-101, is expected to enter Phase I human trials in 1Q 2005. The company anticipates licensing of ZIO-201 by 4Q 2004. ZIOPHARM is actively evaluating and negotiating for other product candidates and plans to in-license a third cancer therapy by 2Q 2005. Each product candidate undergoes a tightly managed evaluation process leveraging the company's management team's combined 100+ years of oncology experience in clinical development, regulatory strategy, business development and product commercialization.

300 George Street
New Haven, Connecticut 06511
  203 848 1234
  info@ziopharm.com

ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for the prevention or treatment of significant human diseases. Using its proven product discovery engine, comprising genomics, bioinformatics, protein chemistry and preclinical biology, ZymoGenetics has generated a broad pipeline of proprietary product candidates. ZymoGenetics intends to commercialize these products through internal development, collaborations with biopharmaceutical partners, and out-licensing of its extensive patent portfolio.

Seattle, Washington

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.